A novel device for rapid and noninvasive volatile metabolite-based screening and diagnosis of multiple disease states

Active Cooperative Agreement Awarded Last action

Award ID
U01TR004072
Recipient
Awarding agency
Obligated
$7,596,881

Award facts

Completion date 87% complete
Place of performance
Boston, MA 02115, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Humans emit an array of volatile organic compounds (VOCS) as part of normal metabolism. There are metabolic shifts in many disease states, and animals with highly sensitive olfactory systems can be trained to identify patients with certain diseases based on their characteristic scent. We seek to translate detection of these unique VOCS emanating through the skin to a more robust, standardized, and mechanized platform, readily adaptable for the screening, diagnosis, and monitoring of a variety of human disease states with distinct pathophysiologies. We hypothesize that systemic metabolic derangements in many high burden infectious, inflammatory, metabolic, malignant, psychiatric, and neurologic diseases can be identified via skin emissions. We will adapt a novel, portable gas chromatography- differential mobility spectrometry (GC-DMS) device that rapidly examines volatile samples directly at the point of care for the assessment of these skin volatile metabolite signatures. This device is highly sensitive, allowing a comprehensive and biologically representative assessment of the landscape of human volatile emissions, is more robust to confounding and environmental factors than many other gas sensing devices, has a long track record of successful use in various real-world sensing applications, and is already undergoing commercial development, which will greatly facilitate its rapid development for the skin VOC-based diagnosis of these 20 disease states. We propose further development and rigorous evaluation of this scent-based diagnostic approach to these disease states, (1) integrating additional process analytical technologies (PATS) to ensure instrumental accuracy and precision between samples and devices through repeated, high-volume patient testing over time and modifying the device inlet for skin volatile analysis, (2) identifying and validating GC- DMS signatures and the corresponding set of skin volatile metabolites that distinguish individuals with and without each of these 20 disease states using machine learning methods, integrating automated detection of these signatures on the GC-DMS device, and (3) developing a wearable sensor for at least one disease with a simple volatile signature, determining the test characteristics of this wearable diagnostic device. A lack of reproducibility is a major issue plaguing the field of volatile metabolite analysis, often due to confounding and study design flaws. We will make every effort to minimize and eliminate any sources of confounding, bias, and extraneous variability as we develop and evaluate this scent-based diagnostic approach, to yield generalizable signatures for each disease state. Ultimately, successful completion of these aims will yield rapid, noninvasive skin volatile metabolite assays for the screening, diagnosis, and monitoring of each of these diseases, with a clear, binary (yes/no) assessment of whether the individual has evidence of one or more of these diseases, facilitating early administration of appropriate therapeutics in these patients and mitigating the clinical consequences of each of these diseases.

Transactions

Action Obligated Date
Amendment $1,184,627
Amendment $1,190,094
Amendment $1,208,710
Amendment $982,580
Amendment $982,580
Amendment $1,024,145
Original award $1,024,145

Subawards

Subrecipient Amount Awarded
University Of Massachusetts The objective of this subcontract is to analyze GC-DMS volatile metabolite signal data from Dr. Koo’s research team at Brigham and Women’s… $218,638
Vox Biomedical LLC The request for U01 support is being sought to integrate skin VOC detection capabilities not the mcroAnalyzer instrument gas chromatography and differentials… $902,886

Quick answers

Who received award U01TR004072?

U01TR004072 was awarded to Brigham & Womens Hospital Inc. by National Center for Advancing Translational Sciences (National Institutes of Health) on July 10, 2022.

How much is award U01TR004072 worth?

$7,596,881 has been obligated on U01TR004072.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login